Clinical-pathological Characterization and Outcomes of Renal Cell Carcinoma in Latin American
Renal Cell Cancer Registry in Latin American Clinical-phatological Characterization and Outcomes of Renal Cell Carcinoma in Latin America
1 other identifier
observational
211
1 country
16
Brief Summary
Observational study, retrospective and prospective, of an analytical nature. Data will be collected from medical records and/or through contact with physicians and institutions (secondary data collection). Patients included retrospectively or prospectively will be followed during the data collection period for the evaluation of treatments and survival. No intervention is planned in this protocol.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2022
16 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 20, 2021
CompletedFirst Posted
Study publicly available on registry
January 11, 2022
CompletedStudy Start
First participant enrolled
September 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 11, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
July 11, 2024
CompletedFebruary 12, 2025
February 1, 2025
1.9 years
December 20, 2021
February 11, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Build a real-life renal cell cancer database in Brazil and Latin America
2022
Secondary Outcomes (7)
Sociodemographic characteristics checklist
2022
Clinicopathological characteristics of patients with renal cell cancer checklist
2022
Characteristics of systemic treatment checklist
2022
Time between diagnosis and start of treatment.
2022
Causes of delay or discontinuation of each treatment checklist
2022
- +2 more secondary outcomes
Study Arms (1)
Patients with pathological diagnosis of renal cell carcinoma
Patients aged 18 years or older, who have been diagnosed with renal cell carcinoma (new case or recurrence) since January 2015 and during the study recruitment period.
Interventions
This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
Eligibility Criteria
Patients aged 18 years or older, who have been diagnosed with renal cell carcinoma (new case or recurrence) since January 2015 and during the study recruitment period.
You may qualify if:
- Patients ≥ 18 years of age;
- Proven histology of renal cell carcinoma (any subtype);
- Pathological diagnosis of renal cell carcinoma in January 2015 or later and new cases diagnosed during the period of recruitment of each center;
- Have the medical record available and suitable for collecting data on patient characteristics, treatment and outcome.
You may not qualify if:
- Synchronous or other primary tumor within the last 3 years (except thyroid cancer or non melanoma skin).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Latin American Cooperative Oncology Grouplead
- Ipsencollaborator
Study Sites (16)
CINPAM - Centro Integrado de Pesquisa da Amazônia
Manaus, Amazonas, 69.020-030, Brazil
Oncocentro Ceará (Rede D'or)
Fortaleza, Ceará, 60.135-237, Brazil
Hospital Evangélico de Cachoeiro de Itapemirim - Centro de Pesquisas Clínicas em Oncologia (CPCO)
Cachoeiro de Itapemirim, Espírito Santo, 29.308-065, Brazil
Santa Casa de Misericórdia de Feira de Santana
Feira de Santana, Estado de Bahia, 44.051-754, Brazil
NOB - Núcleo de Oncologia da Bahia (Oncoclínicas)
Salvador, Estado de Bahia, 40.170-110, Brazil
Onco-Vida Instituto Especializado de Oncologia
Brasília, Federal District, 70.390-700, Brazil
Hospital do Câncer do Maranhão Dr. Tarquínio Lopes Filho
São Luís, Maranhão, 65.015-460, Brazil
Clinica Prognóstica - Centro de Pesquisa Clínica Onconeo
Campo Grande, Mato Grosso do Sul, 79.002-061, Brazil
ICTR - Instituto do Câncer e Transplante de Curitiba
Curitiba, Paraná, 80.510-130, Brazil
Hospital Napoleão Laureano
João Pessoa, Paraíba, 58.013-140, Brazil
Hospital Porto Dias
Belém, Pará, 66.093-032, Brazil
CPO - Centro de Pesquisa em Oncologia do Hospital São Lucas da PUCRS
Porto Alegre, Rio Grande do Sul, 90.619-900, Brazil
Clínica de Hematologia e Oncologia Viver
Santa Maria, Rio Grande do Sul, 97.015-450, Brazil
CTTB - Centro de Tratamento de Tumores Botafogo (Oncoclínicas)
Rio de Janeiro, 22.250-905, Brazil
Hemomed Instituto de Oncologia e Hematologia
São Paulo, 01.236-030, Brazil
CPO - Centro Paulista de Oncologia (Oncoclínicas)
São Paulo, 04.538-135, Brazil
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
André Poisl Fay
Latin American Cooperative Oncology Group
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 20, 2021
First Posted
January 11, 2022
Study Start
September 1, 2022
Primary Completion
July 11, 2024
Study Completion
July 11, 2024
Last Updated
February 12, 2025
Record last verified: 2025-02
Data Sharing
- IPD Sharing
- Will not share